Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis.
Clozapine may produce agranulocytosis in 1-2% of patients treated with it for 4 weeks or longer. Three mechanisms have been suggested: a direct toxic effect of metabolite of clozapine, an immunologic mechanism or a combination of both. N-desmethylclozapine, the major metabolite of clozapine, has been reported to be more toxic than clozapine itself (Gerson et al., 1994). In this study, plasma levels of clozapine and desmethylclozapine were measured in five patients who developed agranulocytosis. The levels of both parent compound and metabolite were within the range found in other patients and below the toxic range. If a toxic mechanism is involved in clozapine-induced agranulocytosis, an additional vulnerability factor must be important.
Hasegawa
M
M
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-5000.
Cola
P A
PA
Meltzer
H Y
HY
D000328:Adult; D000380:Agranulocytosis / Q000097:blood / Q000139:chemically induced*; D003024:Clozapine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
C058272:norclozapine; D003024:Clozapine